Do analysts rate XRTX or CALC?

CalciMedica has a consensus price target of $50.00, suggesting a potential upside of 2,504.17%. Given CalciMedica's stronger consensus rating and higher probable upside, analysts clearly believe CalciMedica is more favorable than XORTX Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CalciMedica 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has stronger earnings and valuation, XRTX or CALC?

XORTX Therapeutics is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XORTX Therapeutics N/A N/A -$2.66M -$2.73 N/A CalciMedica N/A N/A -$29.56M -$6.80 N/A

Is XRTX or CALC more profitable?

XORTX Therapeutics' return on equity of -137.85% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets XORTX Therapeutics N/A -137.85% -108.16% CalciMedica N/A -863.40% -155.24%

Does the media favor XRTX or CALC?

In the previous week, XORTX Therapeutics had 3 more articles in the media than CalciMedica. MarketBeat recorded 5 mentions for XORTX Therapeutics and 2 mentions for CalciMedica. CalciMedica's average media sentiment score of 0.36 beat XORTX Therapeutics' score of 0.27 indicating that CalciMedica is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XORTX Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CalciMedica 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ADIL or XRTX?

Adial Pharmaceuticals currently has a consensus price target of $15.63, indicating a potential upside of 221.50%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Adial Pharmaceuticals is more favorable than XORTX Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, ADIL or XRTX?

XORTX Therapeutics is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adial Pharmaceuticals N/A N/A -$7.98M -$14.73 N/A XORTX Therapeutics N/A N/A -$2.66M -$2.73 N/A

Is ADIL or XRTX more profitable?

XORTX Therapeutics' return on equity of -137.85% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Adial Pharmaceuticals N/A -203.87% -512.41% XORTX Therapeutics N/A -137.85% -108.16%

Does the media refer more to ADIL or XRTX?

In the previous week, XORTX Therapeutics had 3 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 5 mentions for XORTX Therapeutics and 2 mentions for Adial Pharmaceuticals. XORTX Therapeutics' average media sentiment score of 0.27 beat Adial Pharmaceuticals' score of 0.00 indicating that XORTX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral XORTX Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ZIVO or XRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ZIVO or XRTX more profitable?

ZIVO Bioscience's return on equity of 0.00% beat XORTX Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% XORTX Therapeutics N/A -137.85% -108.16%

Does the media favor ZIVO or XRTX?

In the previous week, XORTX Therapeutics had 4 more articles in the media than ZIVO Bioscience. MarketBeat recorded 5 mentions for XORTX Therapeutics and 1 mentions for ZIVO Bioscience. XORTX Therapeutics' average media sentiment score of 0.27 beat ZIVO Bioscience's score of 0.00 indicating that XORTX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ZIVO Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral XORTX Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer XRTX or SCNX?

Scienture has a consensus price target of $1.50, indicating a potential upside of 378.47%. Given Scienture's stronger consensus rating and higher possible upside, analysts clearly believe Scienture is more favorable than XORTX Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scienture 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is XRTX or SCNX more profitable?

Scienture's return on equity of -53.51% beat XORTX Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets XORTX Therapeutics N/A -137.85% -108.16% Scienture N/A -53.51% -42.47%

Does the media prefer XRTX or SCNX?

In the previous week, XORTX Therapeutics had 4 more articles in the media than Scienture. MarketBeat recorded 5 mentions for XORTX Therapeutics and 1 mentions for Scienture. XORTX Therapeutics' average media sentiment score of 0.27 beat Scienture's score of 0.00 indicating that XORTX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XORTX Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scienture 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate XRTX or MBRX?

Moleculin Biotech has a consensus target price of $3.00, suggesting a potential upside of 288.05%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Moleculin Biotech is more favorable than XORTX Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has stronger valuation & earnings, XRTX or MBRX?

XORTX Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XORTX Therapeutics N/A N/A -$2.66M -$2.73 N/A Moleculin Biotech N/A N/A -$33.56M -$7.13 N/A

Is XRTX or MBRX more profitable?

XORTX Therapeutics' return on equity of -137.85% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets XORTX Therapeutics N/A -137.85% -108.16% Moleculin Biotech N/A -143.51% -24.53%

Does the media prefer XRTX or MBRX?

In the previous week, XORTX Therapeutics had 3 more articles in the media than Moleculin Biotech. MarketBeat recorded 5 mentions for XORTX Therapeutics and 2 mentions for Moleculin Biotech. XORTX Therapeutics' average media sentiment score of 0.27 beat Moleculin Biotech's score of -0.27 indicating that XORTX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XORTX Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

XORTX Therapeutics (XRTX) Competitors

$1.92 +0.26 (+15.66%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.88 -0.04 (-2.34%)

As of 09/18/2026 07:59 PM Eastern

Compare

XRTX vs. CALC, ADIL, ZIVO, SCNX, and MBRX

Should you buy XORTX Therapeutics stock or one of its competitors? XORTX Therapeutics's main competitors and comparable companies include CalciMedica (CALC), Adial Pharmaceuticals (ADIL), ZIVO Bioscience (ZIVO), Scienture (SCNX), and Moleculin Biotech (MBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does XORTX Therapeutics compare to CalciMedica?

XORTX Therapeutics (NASDAQ:XRTX) and CalciMedica (NASDAQ:CALC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

XORTX Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, CalciMedica has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

XORTX Therapeutics is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.73	N/A
CalciMedica	N/A	N/A	-$29.56M	-$6.80	N/A

CalciMedica has a consensus price target of $50.00, suggesting a potential upside of 2,504.17%. Given CalciMedica's stronger consensus rating and higher probable upside, analysts clearly believe CalciMedica is more favorable than XORTX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CalciMedica	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, XORTX Therapeutics had 3 more articles in the media than CalciMedica. MarketBeat recorded 5 mentions for XORTX Therapeutics and 2 mentions for CalciMedica. CalciMedica's average media sentiment score of 0.36 beat XORTX Therapeutics' score of 0.27 indicating that CalciMedica is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XORTX Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CalciMedica	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.2% of XORTX Therapeutics shares are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by insiders. Comparatively, 28.3% of CalciMedica shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

XORTX Therapeutics' return on equity of -137.85% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-137.85%	-108.16%
CalciMedica	N/A	-863.40%	-155.24%

Summary

CalciMedica beats XORTX Therapeutics on 7 of the 13 factors compared between the two stocks.

How does XORTX Therapeutics compare to Adial Pharmaceuticals?

Adial Pharmaceuticals (NASDAQ:ADIL) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

XORTX Therapeutics' return on equity of -137.85% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-203.87%	-512.41%
XORTX Therapeutics	N/A	-137.85%	-108.16%

XORTX Therapeutics is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.73	N/A

Adial Pharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are owned by institutional investors. 8.0% of Adial Pharmaceuticals shares are owned by company insiders. Comparatively, 6.9% of XORTX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, XORTX Therapeutics had 3 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 5 mentions for XORTX Therapeutics and 2 mentions for Adial Pharmaceuticals. XORTX Therapeutics' average media sentiment score of 0.27 beat Adial Pharmaceuticals' score of 0.00 indicating that XORTX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adial Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
XORTX Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adial Pharmaceuticals currently has a consensus price target of $15.63, indicating a potential upside of 221.50%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Adial Pharmaceuticals is more favorable than XORTX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Adial Pharmaceuticals beats XORTX Therapeutics on 7 of the 13 factors compared between the two stocks.

How does XORTX Therapeutics compare to ZIVO Bioscience?

ZIVO Bioscience (NASDAQ:ZIVO) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

XORTX Therapeutics has lower revenue, but higher earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	850.98	-$7.78M	-$1.40	N/A
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.73	N/A

In the previous week, XORTX Therapeutics had 4 more articles in the media than ZIVO Bioscience. MarketBeat recorded 5 mentions for XORTX Therapeutics and 1 mentions for ZIVO Bioscience. XORTX Therapeutics' average media sentiment score of 0.27 beat ZIVO Bioscience's score of 0.00 indicating that XORTX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ZIVO Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
XORTX Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are held by institutional investors. 48.9% of ZIVO Bioscience shares are held by company insiders. Comparatively, 6.9% of XORTX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ZIVO Bioscience has a beta of 0.16, meaning that its share price is 84% less volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ZIVO Bioscience's return on equity of 0.00% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
XORTX Therapeutics	N/A	-137.85%	-108.16%

Summary

ZIVO Bioscience and XORTX Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does XORTX Therapeutics compare to Scienture?

XORTX Therapeutics (NASDAQ:XRTX) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

0.2% of XORTX Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Scienture shares are owned by institutional investors. 6.9% of XORTX Therapeutics shares are owned by company insiders. Comparatively, 21.4% of Scienture shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Scienture's return on equity of -53.51% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-137.85%	-108.16%
Scienture	N/A	-53.51%	-42.47%

XORTX Therapeutics has higher earnings, but lower revenue than Scienture. XORTX Therapeutics is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.73	N/A
Scienture	$430K	29.94	-$41.51M	-$2.10	N/A

XORTX Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Scienture has a beta of 3.25, suggesting that its share price is 225% more volatile than the broader market.

In the previous week, XORTX Therapeutics had 4 more articles in the media than Scienture. MarketBeat recorded 5 mentions for XORTX Therapeutics and 1 mentions for Scienture. XORTX Therapeutics' average media sentiment score of 0.27 beat Scienture's score of 0.00 indicating that XORTX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XORTX Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scienture	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Scienture has a consensus price target of $1.50, indicating a potential upside of 378.47%. Given Scienture's stronger consensus rating and higher possible upside, analysts clearly believe Scienture is more favorable than XORTX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Scienture beats XORTX Therapeutics on 11 of the 14 factors compared between the two stocks.

How does XORTX Therapeutics compare to Moleculin Biotech?

XORTX Therapeutics (NASDAQ:XRTX) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

XORTX Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

0.2% of XORTX Therapeutics shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by company insiders. Comparatively, 18.0% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

XORTX Therapeutics' return on equity of -137.85% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-137.85%	-108.16%
Moleculin Biotech	N/A	-143.51%	-24.53%

Moleculin Biotech has a consensus target price of $3.00, suggesting a potential upside of 288.05%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Moleculin Biotech is more favorable than XORTX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

XORTX Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.73	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A

In the previous week, XORTX Therapeutics had 3 more articles in the media than Moleculin Biotech. MarketBeat recorded 5 mentions for XORTX Therapeutics and 2 mentions for Moleculin Biotech. XORTX Therapeutics' average media sentiment score of 0.27 beat Moleculin Biotech's score of -0.27 indicating that XORTX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XORTX Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Moleculin Biotech beats XORTX Therapeutics on 8 of the 13 factors compared between the two stocks.

Get XORTX Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XRTX vs. The Competition

Export

Metric	XORTX Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.49M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-0.70	797.25	275.49	25.40
Price / Sales	N/A	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	1.28	10.53	10.46	6.33
Net Income	-$2.66M	$2.82B	$3.49B	$358.33M
7 Day Performance	-17.60%	1.69%	0.59%	1.12%
1 Month Performance	-4.95%	0.24%	-1.74%	-2.39%
1 Year Performance	-53.78%	3.95%	18.13%	5.35%

XORTX Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XRTX XORTX Therapeutics	0.9055 of 5 stars	$1.92 +15.7%	N/A	-55.3%	$3.49M	N/A	N/A	N/A	News Coverage Gap Up High Trading Volume
CALC CalciMedica	3.975 of 5 stars	$2.12 -7.8%	$50.00 +2,258.5%	-87.3%	$15.67M	N/A	N/A	30
ADIL Adial Pharmaceuticals	2.2231 of 5 stars	$5.99 +1.0%	$15.63 +160.9%	-44.5%	$15.57M	N/A	N/A	20	News Coverage
ZIVO ZIVO Bioscience	N/A	$3.60 +15.7%	N/A	-75.4%	$15.17M	$15.85K	N/A	10	News Coverage Gap Down
SCNX Scienture	2.366 of 5 stars	$0.36 -2.6%	$1.50 +319.6%	-64.9%	$15.07M	$430K	N/A	N/A	News Coverage Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XRTX) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XORTX Therapeutics (XRTX) Competitors

XRTX vs. CALC, ADIL, ZIVO, SCNX, and MBRX

How does XORTX Therapeutics compare to CalciMedica?

Summary

How does XORTX Therapeutics compare to Adial Pharmaceuticals?

Summary

How does XORTX Therapeutics compare to ZIVO Bioscience?

Summary

How does XORTX Therapeutics compare to Scienture?

Summary

How does XORTX Therapeutics compare to Moleculin Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XRTX vs. The Competition

XORTX Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XORTX Therapeutics (XRTX) Competitors

XRTX vs. CALC, ADIL, ZIVO, SCNX, and MBRX

How does XORTX Therapeutics compare to CalciMedica?

Which has more volatility & risk, XRTX or CALC?

Which has stronger earnings and valuation, XRTX or CALC?

Do analysts rate XRTX or CALC?

Does the media favor XRTX or CALC?

Do institutionals & insiders have more ownership in XRTX or CALC?

Is XRTX or CALC more profitable?

Summary

How does XORTX Therapeutics compare to Adial Pharmaceuticals?

Is ADIL or XRTX more profitable?

Which has preferable earnings & valuation, ADIL or XRTX?

Which has more volatility and risk, ADIL or XRTX?

Do insiders & institutionals have more ownership in ADIL or XRTX?

Does the media refer more to ADIL or XRTX?

Do analysts rate ADIL or XRTX?

Summary

How does XORTX Therapeutics compare to ZIVO Bioscience?

Which has better valuation and earnings, ZIVO or XRTX?

Does the media favor ZIVO or XRTX?

Do institutionals & insiders have more ownership in ZIVO or XRTX?

Which has more risk & volatility, ZIVO or XRTX?

Do analysts prefer ZIVO or XRTX?

Is ZIVO or XRTX more profitable?

Summary

How does XORTX Therapeutics compare to Scienture?

Do insiders and institutionals believe in XRTX or SCNX?

Is XRTX or SCNX more profitable?

Which has better valuation & earnings, XRTX or SCNX?

Which has more volatility and risk, XRTX or SCNX?

Does the media prefer XRTX or SCNX?

Do analysts prefer XRTX or SCNX?

Summary

How does XORTX Therapeutics compare to Moleculin Biotech?

Which has more risk & volatility, XRTX or MBRX?

Do institutionals and insiders believe in XRTX or MBRX?

Is XRTX or MBRX more profitable?

Do analysts rate XRTX or MBRX?

Which has stronger valuation & earnings, XRTX or MBRX?

Does the media prefer XRTX or MBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XRTX vs. The Competition

XORTX Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools